The latest price target for Avalo Therapeutics (NASDAQ:AVTX) was reported by Piper Sandler on February 28, 2025. The analyst firm set a price target for $48.00 expecting AVTX to rise to within 12 months (a possible 562.07% upside). 5 analyst firms have reported ratings in the last year.

The latest analyst rating for Avalo Therapeutics (NASDAQ:AVTX) was provided by Piper Sandler, and Avalo Therapeutics initiated their overweight rating.

The last upgrade for Avalo Therapeutics Inc happened on April 16, 2024 when Oppenheimer raised their price target to $35. Oppenheimer previously had a perform for Avalo Therapeutics Inc.

The last downgrade for Avalo Therapeutics Inc happened on June 27, 2023 when Oppenheimer changed their price target from N/A to N/A for Avalo Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Avalo Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Avalo Therapeutics was filed on February 28, 2025 so you should expect the next rating to be made available sometime around February 28, 2026.

While ratings are subjective and will change, the latest Avalo Therapeutics (AVTX) rating was a initiated with a price target of $0.00 to $48.00. The current price Avalo Therapeutics (AVTX) is trading at is $7.25, which is within the analyst’s predicted range.